Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
CLEVELAND, Jan. 31, 2022 /PRNewswire/ -- NovelMed Therapeutics announced today that its Investigational New Drug Application (IND) to initiate clinical trials of its NM8074 biologic has been cleared ...
RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its oral Factor D inhibitor, BCX9930, demonstrated >99 percent ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
In this analysis of patients with myeloperoxidase-ANCA-positive AAV, all urinary complement C3 fragment levels were elevated significantly compared with healthy controls (P <.01 for all).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results